Femur Head Necrosis: Clinical Trials

9 trials for Femur Head Necrosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 active not recruiting, 1 recruiting, 1 suspended. 9 Phase 2, 2 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 29Completed 5, Active not recruiting 1, Recruiting 1, Suspended 1, Unknown 1
Phase 12Completed 1, Suspended 1
Phase 31Unknown 1

Follow Femur Head Necrosis: new trials by email Literature Review of Femur Head Necrosis trials Research Report on Femur Head Necrosis

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ONFH)
Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#), core decompression - Osteonecrosis of Femoral Head
Phase 1 / Phase 2SuspendedSclnow Biotechnology Co., Ltd.302026-12-312026-04-23
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
Alendronate Sodium - Sickle Cell Disease, Sickle Cell Anemia
Phase 2RecruitingUniversity of California, Davis302026-03-092026-07-16
A Phase II Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral Head
RAB001 high dose, RAB001 medium dose, RAB001 low dose - Osteonecrosis, Osteonecrosis of the Femoral Head
Phase 2Active not recruitingZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.1612024-12-242026-03-24
Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head
XCEL-MT-OSTEO-ALPHA, Standard treatment - Avascular Necrosis of Femur Head
Phase 1 / Phase 2CompletedBanc de Sang i Teixits232015-05-052020-01-21
Evaluation of Mesenchymal Stem Cells to Treat Avascular Necrosis of the Hip
Cultured autologous Mesenchymal Cells - Avascular Necrosis of the Femoral Head
Phase 2CompletedUniversidad Autonoma de Madrid262014-02-012021-10-14
PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells
bone marrow aspirate - Osteonecrosis of the Femoral Head
Phase 2CompletedRed de Terapia Celular32012-07-012017-03-30
Implantation of Bone Marrow Cells to Treat Avascular Necrosis of Femoral Head (ANFH)
core decompression, Enriched BMCs implantation combined with core decompression - Avascular Necrosis of Femur Head
Phase 2 / Phase 3UnknownGuangdong Provincial People's Hospital602009-03-012012-08-14
Effectiveness of Two Types of Treatment in Restoring Muscle After Hip or Knee Surgery
Essential amino acid supplement, Ketoconazole, Placebo - Hip Fracture, Osteoarthritis
Phase 2CompletedUniversity of Arkansas402006-10-012014-06-02
Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head
Core decompression/PREOB® implantation, Core decompression/BMC implantation - Avascular Necrosis of Femur Head
Phase 2CompletedErasme University Hospital822003-10-012016-09-07

Narrower conditions

Legg-Calve-Perthes Disease (4)  ·  Osteonecrosis (4)  ·  Musculoskeletal Diseases (2)  ·  Anemia, Sickle Cell (1)  ·  Bone Diseases (1)  ·  Hip Fractures (1)  ·  Osteoarthritis (1)

Broader conditions

Bone Diseases (8)  ·  Necrosis (8)  ·  Pathologic Processes (8)  ·  Pathological Conditions, Signs and Symptoms (8)  ·  Musculoskeletal Diseases (7)  ·  Osteonecrosis (5)  ·  Anemia (1)  ·  Anemia, Hemolytic (1)  ·  Anemia, Hemolytic, Congenital (1)  ·  Arthritis (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Femoral Fractures (1)  ·  Fractures, Bone (1)  ·  Genetic Diseases, Inborn (1)

Interventions

Alendronate (2)  ·  Ketoconazole (1)

Sponsors

Banc de Sang i Teixits (1)  ·  Erasme University Hospital (1)  ·  Guangdong Provincial People's Hospital (1)  ·  Red de Terapia Celular (1)  ·  Sclnow Biotechnology Co., Ltd. (1)  ·  Universidad Autonoma de Madrid (1)  ·  University of Arkansas (1)  ·  University of California, Davis (1)  ·  ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. (1)

Countries

Spain (3)  ·  China (2)  ·  United States (2)  ·  Belgium (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)

Top investigators

Arny Ferrando, PhD (1)  ·  Enrique Gomez-Barrena, Prof (1)  ·  Lei Guo, Dr. (1)  ·  Oyebimpe O Adesina, MD, MS (1)

Results publications

PMID 25315149, PMID 25769789, PMID 32678055, PMID 33535589

NIH funding

K23HL148310 (1), R01AR052293 (1)